Document is current
Any future updates will be listed below
-
Authors
Gao, Xinghua
Pan, Weili
Zheng, Min
Li, Fuqiu
Dong, Xiuqin
Lv, Dong
Guo, Zaipei
Li, Jinnan
Wang, Xuan
Geng, Songmei
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03364309 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab
https://doi.org/10.1007/s12325-024-03030-5
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 19 August 2024
Accepted: 9 October 2024
First Online: 13 November 2024
Declarations
:
: Xuan Wang and Jinnan Li are employees of Eli Lilly and Company, and Jinnan Li owns minor shares of Eli Lilly and Company. The other authors have no conflicts of interest to disclose.
: The study received approval from the relevant ethics committee(s) and was conducted in accordance with the Good Clinical Practices guidelines, in line with the Declaration of Helsinki of 1964, and applicable local laws and regulations. Written informed consent was obtained from all patients before inclusion, and the study was registered at clinical trials. gov (NCT03364309).
